BioBridgeX
Log inCompare quotes
CMC / Manufacturing

Drug Substance: Small Molecule / API CDMOs

Free for buyersNeutral marketplace
Quick answer

Drug Substance: Small Molecule / API is the GMP manufacture of the active pharmaceutical ingredient itself, the purified small molecule that becomes your drug. You source it once a candidate is selected and need material for tox, clinical, or commercial supply. On BioBridgeX, buyers compare qualified API CDMOs and contract under one agreement, free for buyers.

Drug Substance: Small Molecule / API CDMOs on BioBridgeX

We are qualifying and publishing Drug Substance: Small Molecule / API CDMOs now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What is Drug Substance: Small Molecule / API and when do you need it?

Drug substance for a small molecule is the active pharmaceutical ingredient, the purified chemical compound that does the therapeutic work, before it is formulated into a tablet, capsule, or injectable. This category covers the people who actually make that material at quality and scale: route scouting and process chemistry, scale-up from grams to kilos, GMP manufacture of clinical and commercial API, isolation and purification, particle size and polymorph control, and the analytical work that proves identity, purity, and impurity profile. It is the chemistry-heavy half of CMC, distinct from the drug product side that turns your API into a finished dosage form.

You need an API CDMO the moment you have a committed candidate and need real material in hand. The first call is usually non-GMP material for IND-enabling toxicology, where the test article dosed in animals has to match what will eventually reach patients. Then comes GMP drug substance for Phase 1, with tighter demands at each later phase as the route is locked, impurities are qualified, and the process is characterized for validation. By the time you approach an NDA you need a registered, validated commercial process and a defined regulatory starting material (RSM) strategy that a reviewer will accept. Each of those is a different conversation, and many sponsors change or add a manufacturer along the way.

Two things make small molecule API its own discipline rather than generic chemistry. First, the synthetic route is a long-lived decision: the chemistry you scale at Phase 1 shapes cost of goods, impurity control, and supply risk for the life of the product, and changing it late triggers comparability work and regulatory questions. Second, many oncology and CNS molecules are highly potent (HPAPI) or cytotoxic, which requires containment, occupational exposure banding, and dedicated suites that a standard API plant may not have. Getting the route and the containment fit right early is where this work either de-risks the program or quietly creates a problem you pay for later.

What does a Drug Substance: Small Molecule / API CDMO actually do?

An API CDMO takes your synthetic target and turns it into a reproducible, documented manufacturing process that yields material a regulator and a formulation team will accept. The work is sequential and each step feeds the next, which is why a single capable partner across the chain often beats stitching together separate suppliers.

Beyond making the molecule, a good API partner owns the analytical and regulatory story that travels with the drug substance. That means a validated suite of release and stability methods, a genotoxic and elemental impurity assessment, a nitrosamine evaluation that has become non-negotiable for small molecules, and the CMC sections of your regulatory filing. The deliverable is not just a drum of powder; it is powder plus a Certificate of Analysis, a batch record, and a data package that supports the claim you are about to make to the FDA or EMA.

  • Route scouting and process chemistry: design a synthesis that is safe, scalable, and economical, then define the regulatory starting materials under ICH Q11.
  • Scale-up and tech transfer: move from medicinal-chemistry grams to kilo-lab and pilot-plant batches, controlling exotherms, mixing, and reaction kinetics that behave differently at scale.
  • GMP manufacture under ICH Q7: produce non-GMP tox material and GMP clinical or commercial API, with batch records, in-process controls, and full traceability.
  • Isolation, crystallization, and solid-state control: manage polymorph form, particle size, and crystallinity, since the wrong form changes solubility, bioavailability, and stability.
  • Impurity control and qualification: identify, quantify, and qualify process and degradation impurities, including genotoxic, elemental (ICH Q3D), and nitrosamine risk.
  • Analytical development and QC release: develop and validate identity, assay, related-substances, and stability-indicating methods (HPLC, GC, mass spec, XRPD) and run ICH stability programs.
  • Process characterization and validation: define the design space, set critical process parameters, and run process performance qualification (PPQ) batches for a commercial filing.
  • CMC regulatory support: author Module 3 drug substance sections, build the control strategy, and supply the data that backs an IND, IMPD, NDA, or MAA.

How to choose a Drug Substance: Small Molecule / API CDMO?

The honest filter is fit to where your program actually is, not the size of the network. A CDMO that excels at multi-tonne commercial API may be slow and expensive for a 2 kg Phase 1 campaign, and a nimble kilo-lab shop may not have the validated quality systems to carry you to a commercial filing. Decide whether you are buying speed and flexibility now or a manufacturer you can stay with through approval, and weight the criteria accordingly. The cheapest quote rarely wins here, because a botched campaign or a route you have to redevelop costs far more in lost program time than the savings.

Score two or three candidates against the same written scope (target quantity, purity spec, GMP grade, timeline, and containment level) so you are comparing like for like. Use the checklist below to separate a partner that will hold up under an inspection and a filing from one that looks good on a slide deck.

  • Quality and GxP status: current GMP under ICH Q7, a clean recent FDA or EMA inspection history, and the right grade for the stage (non-GMP tox vs GMP clinical vs validated commercial).
  • Capacity and lead time: real reactor volume in the range you need, an honest current queue, and lead times for raw materials and starting materials that often sit on the critical path.
  • Modality and indication fit: genuine small molecule expertise, plus containment and occupational exposure banding for HPAPI, cytotoxic, or highly potent oncology compounds if that is your chemistry.
  • Region and regulatory track record: a site whose filings have cleared in the markets you plan to sell in, with experience handling nitrosamine, genotoxic, and elemental impurity questions.
  • Data quality and documentation: validated analytical methods, complete batch records, a Certificate of Analysis you can rely on, ICH stability data, and data integrity practices that survive an audit.
  • IP and confidentiality: a clear CDA before disclosure, defined ownership of process know-how and any improvements, and segregation so your route is not shared with a competitor's program.

Frequently asked questions

What is the difference between drug substance and drug product for a small molecule?
Drug substance is the active pharmaceutical ingredient itself, the purified small molecule made by synthesis and isolation. Drug product is the finished dosage form a patient takes: the tablet, capsule, or injectable made by blending that API with excipients. An API CDMO makes and releases the drug substance; a drug product CDMO formulates and fills it. Some sites do both, but they are different capabilities, different quality systems, and usually different facilities, so confirm which one a supplier actually offers before you scope the work.
When do I need non-GMP versus GMP API?
Non-GMP material is fine for early process development and for IND-enabling toxicology, where the goal is to characterize the candidate and the test article simply has to be representative of clinical material. You need GMP drug substance, made under ICH Q7, the moment material is destined for humans, which means your Phase 1 clinical supply onward. The grade is not a quality judgment; non-GMP is not sloppy, it is fit for a non-clinical purpose. Paying GMP prices for tox material nobody will dose in a patient is wasted budget, and dosing non-GMP material in the clinic is a serious problem.
Why does the synthetic route matter so much, and when should it be locked?
The route you scale determines cost of goods, your impurity profile, supply-chain risk, and how defensible your regulatory starting material is. Changing it late forces comparability studies and invites reviewer questions, so it is one of the highest-stakes decisions in the program. Most sponsors keep the early-phase route deliberately flexible, then invest in route optimization and a locked process before pivotal manufacturing and validation. Settle the regulatory starting material strategy under ICH Q11 early, because a reviewer rejecting your proposed RSM can pull steps into GMP that you did not budget for.
What is an HPAPI and does it change how I choose a CDMO?
HPAPI stands for highly potent active pharmaceutical ingredient, a compound active at very low doses, common in oncology and in payloads for antibody-drug conjugates. It changes everything about facility selection. You need a site with containment, occupational exposure banding, dedicated or properly cleaned suites, and cleaning validation that proves cross-contamination is controlled. A standard API plant that is excellent at ordinary small molecules may not be set up to handle potent or cytotoxic material safely. If your molecule is potent, screen for HPAPI capability first, because retrofitting containment is not something you negotiate mid-campaign.
How much API do I need at each stage, and how long does a campaign take?
Quantities scale with the stage: grams to a few kilos for tox and Phase 1, more for Phase 2 and Phase 3 as patient numbers grow, and commercial batches sized to forecast demand. Timelines depend heavily on route complexity, the number of synthetic steps, and raw material lead times, so any single number would mislead. The recurring critical path is not the chemistry itself but sourcing starting materials and reagents, plus analytical method development and stability. Scope the quantity, purity spec, and grade precisely, then ask each CDMO for a campaign timeline against that scope rather than a generic estimate.
How does sourcing an API CDMO through BioBridgeX work?
BioBridgeX is a neutral marketplace with no plant of its own, so it has no incentive to steer your campaign toward a preferred site. You describe the molecule, quantity, grade, containment needs, and timeline, and you are matched with qualified small molecule API CDMOs to compare on capability, capacity, and transparent quotes. It is free for buyers, and suppliers pay a flat 2 percent platform fee. When a program needs more than one supplier, an API maker plus separate analytical or drug product partners, you compare quotes and contract directly with each chosen supplier, in one place.

Source Drug Substance: Small Molecule / API with one contract

Compare transparent quotes from qualified Drug Substance: Small Molecule / API CDMOs, then contract once. Free for buyers.

Compare quotes